Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 4Lymphoid 2Thoracic 1Other hematologic neoplasm 1Gynecologic 1

Conditions

Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 41Specimen Handling 36Carboplatin 34pembrolizumab 32Bevacizumab 32Magnetic Resonance Spectroscopy 29olaparib 19liposomal doxorubicin 16Cisplatin 16Biopsy 16Gemcitabine 15Taxes 12Nivolumab 12Immunoglobulin G 11Disulfides 11Cyclophosphamide 11Topotecan 10Doxorubicin 10fludarabine 9niraparib 7mirvetuximab soravtansine 7Fulvestrant 7trastuzumab deruxtecan 6palbociclib 6durvalumab 6Surveys and Questionnaires 6Megestrol Acetate 6lenvatinib 5dostarlimab 5Radiation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hyaluronoglucosaminidase × Gynecologic × 30 days × Clear all
NCT05256225 2026-06-03

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

National Cancer Institute (NCI)

Phase 3 Recruiting
360 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡